ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

19.12 0.59 −2.99%
Market cap
$3.4B
P/E
8.5×
Fwd P/E
55.6×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Net Income
(271.39) (289.40) (245.19) (235.26) (281.58) (167.87) (215.97) (61.29) 226.45 391.00
Depreciation & Amortization
1.92 2.42 2.43 (0.85) 4.40 5.75 (0.71) (1.98) 6.58 6.34
Non Cash Items (Other)
54.67 75.54 83.49 81.27 129.98 61.29 64.66 61.84 (79.47) (197.74)
Accounts Receivable Change
(5.90) (11.44) (8.75) (9.69) (12.47) (16.12) 2.17 (36.07) (0.47) (22.72)
Change in inventories
(3.30) (1.01) 1.93 (1.74) (3.32) (4.21) 2.42 (28.81) (49.55) (18.20)
Accounts Payable Change
2.24 4.87 (5.62) 4.06 1.27 (1.62) 5.87 4.80 (1.35) (5.29)
Change in payables and accrued liability
15.58 4.21 15.99 6.46 27.57 (8.45) 24.31 93.17 71.06 (19.26)
Change in other assets and liabilities
(2.22) (2.94) (11.75) 4.62 (2.02) 5.58 3.23 (14.95) (15.53) (24.29)
Operating Cash Flow
(208.41) (217.76) (167.47) (151.13) (136.17) (125.66) (114.03) 16.70 157.72 109.84
Capital expenditures
(1.51) (0.81) (2.10) (1.13) (7.59) (1.12) — (0.05) (0.52) (4.69)
Change in intangibles (net)
(8.00) — — — — — — (40.00) — —
Short Term Investments Change (Net)
(252.42) 93.29 (66.24) (164.71) 200.10 (69.98) 73.24 (357.73) (505.09) (692.56)
Long-Term Investments Change (Net)
— — (3.15) — — — — 429.78 328.57 493.53
Other investing activities
14.92 — — — — — — (40.00) 146.52 (98.84)
Investing cash flow
(261.92) 92.47 (71.49) (165.84) 192.51 (71.10) 73.24 32.00 (30.54) (302.56)
Equity Repurchase (Common, Net)
519.49 31.19 306.65 371.85 81.00 18.16 8.20 25.13 6.85 49.88
Other financial activities
14.32 — — — — — — — — —
Financing cash flow
533.81 31.19 306.65 371.85 81.00 18.16 8.20 25.13 6.85 49.88
Exchange Rate Adjustment
0.00 (0.01) 0.00 0.00 (0.01) 0.01 0.01 (0.02) (0.09) 0.03
Change in Cash
63.48 (94.10) 67.69 54.88 137.33 (178.59) (32.59) 73.81 133.93 (142.82)
Beginning Cash
102.51 166.00 71.89 139.58 194.47 331.80 153.21 120.62 194.43 328.36
Ending Cash
166.00 71.89 139.58 194.47 331.80 153.21 120.62 194.43 328.36 185.54
Stock Based Compensation
55.27 75.53 81.56 82.27 84.42 63.62 68.20 66.42 67.05 52.14
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
6.39 (6.31) (8.20) 3.71 11.04 (24.82) 37.99 18.13 4.16 (89.76)
Investments Change (Net)
(252.42) 93.29 (69.38) (164.71) 200.10 (69.98) 73.24 72.05 (176.53) (199.04)
Issuance/Purchase of Shares
519.49 31.19 306.65 371.85 81.00 18.16 8.20 25.13 6.85 49.88
Other line items
Revenue per Employee
0.05 0.29 0.52 0.67 0.74 0.94 1.01 1.21 1.46 1.34

Fold the line items

In millions of $ except per-share values · columns are period end dates